[ad_1]
In order to encourage pharmaceutical companies to resume the development of antibiotics, the UK government has announced the establishment of a licensing model allowing developers to obtain a return on investment ( ROI) sufficient.
A five-year plan for the fight against antimicrobial resistance published by the British government has ambitious goals. Using an electronic prescription, it aims to reduce by 15% the use of antibiotics in humans. In addition, the government wants to have full control of the RAM by 2040.
While pharmaceutical companies have left the antibiotics market due to lack of return on investment, governments around the world are pondering how to bring them back to development to fight AMR, due to overuse of antibiotics and to the genetic adaptation of microbes. On the one hand, funds have been put in place to encourage drug testing with a new mechanism against the most resistant insects. The other part of the initiatives to re-incentivize the development of antibiotics concerns new payment models.
NICE and the NHS England have announced a value-based licensing model in which drug developers would be paid based on the value of drugs for the NHS, rather than the amount of drugs sold. NICE would lead the evaluation of antimicrobials through health technologies. Work on the introduction of the new payment model will begin six months from now, British Secretary of State Britains Health Matt Hanbad told the World Economy Forum 2019 in Davos. in Switzerland, adding that this would encourage companies to invest in the £ 1 billion needed to develop a new drug.
The plan is to allow a predefined amount of antimicrobials each year instead of buying them. This would decouple the return on investment from the quantity of antimicrobials prescribed. According to Hanbad, the NHS would pay the price in advance. In addition, we are discussing the creation of a national tax on antibiotics, which developers could either pay or invest. Last June, FDA Commissioner Scott Gottlieb proposed a similar model that hospitals would allow for antimicrobials.
The AMR community – and many small and medium-sized businesses active in the field – is praised for the decision to finally test a pull mechanism. "It's great to see action after many years of reporting and we thank the British government for taking the lead," said Marc Gitzinger, CEO of Swiss Bioversys and Vice President BEAM Alliance, representing European SMEs focusing on AMR in Europe. . Marc Lemonnier, CEO of French Antabio and also a member of the BEAM Alliance Board of Directors, added: "This announcement represents a clear and unprecedented commitment to the implementation of a business model. the purchase of antibiotics disconnected.The United Kingdom to be applauded. "Also in the United States, the British initiative received support. "A monumental advance for the sector," said Kevin Outterson, executive director of CARB-X, based in the United States. John Rex, one of AMR's leading international opinion leaders, commented in his newsletter: "We have reached this exciting stage, thanks to the work of many people behind DRIVE-AB, the group led by O. Neill UK AMR Review, reviews led by Duke-Margolis, etc. There is of course still work to be done and many questions to be solved: which antibiotics to buy, how much to pay, how to pay, how long to buy? the less we are at the starting point for a new approach to antibiotic reimbursement. "
New antimicrobial payment models to address the failing business model for antimicrobial resistance will be a key theme at the 12th Berlin Life Science Conference "New antimicrobials and AMR Diagnostics 2019". Representatives from NICE and Wellcome Trust will provide more information on the UK's new initiative at the Market Access session on Day Two, chaired by the Global R & D Center for RMA.
BIOCOM expects 350 international AMR experts to attend this two-day conference, supported by UK Trade and Invest, the European consortium ENABLE, GARDP, CARB-X, Novo REPAIR Impact Fund and Biomérieux.
Source link
